Peregrine Pharma (PPHM) Posts Mixed Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Peregrine Pharma (PPHM) Posts Mixed Q4 Results
July 15, 2016 12:01 PM EDT
Noble Financial affirms Peregrine Pharma (Nasdaq: PPHM) witha Buy rating and $1.50 price target after the company announced Q4 and FY16 results on Thursday night.
Analyst Kumaraguru Raja, PhD, noted the following today:
Focus on value creation. Peregrine continues to focus on value creation driven by Avid contract manufacturing...
More
July 14, 2016 8:08 AM EDT
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that the company has entered into an exclusive licensing agreement with University of Texas (UT) Southwestern Medical Center for a novel exosome technology that has potential application as a simple blood test to detect or monitor cancer. The company intends to develop a novel cancer test utilizing internal expertise and then pursue revenue-generating partnering opportunities at an early stage of development.
Tumor exosomes represent small pieces of tumor cells that are released into the blood as tumors grow. Tumor derived exosomes have... More
